# KLOW research dose context — what the literature administered, by component and route > Component-by-component summary of the doses, routes, and durations used in the peer-reviewed KLOW-component research literature. Research context only; not a human dosing recommendation. **What the literature administered** A reference summary of doses, routes, and durations used in the peer-reviewed studies of the four KLOW components. Strictly research-context. Nothing on this page is a recommendation for human use. ## Framing This page summarizes the doses and routes administered in the published research literature of the four KLOW components. It is not a human dosing guide. None of the four peptides is FDA-approved as a systemic or injectable drug, no controlled human dose-response curve has been published for the four-peptide blend, and the 80 mg per-vial composition cited across compounders is a marketplace convention rather than a pharmacopeial dose. The convention used throughout is study-attributed: 'in rats at X microgram/kg via intraperitoneal injection,' not 'an effective dose is.' Doses cited here come directly from the peer-reviewed sources in the references list. ## Canonical research-vial composition The most-cited KLOW research-vial composition across compounders is 80 mg total: GHK-Cu at 50 mg (62.5% by mass), BPC-157 at 10 mg, TB-500 at 10 mg, and KPV at 10 mg [1]. The peptides are co-dissolved at fixed mass ratios in the lyophilized vial; they do not form a single chemical complex. Vendor reconstitution guidance varies — bacteriostatic water or sterile water are typical — and validated stability data after reconstitution is not consistently published. There is no FDA-approved or pharmacopeial KLOW combination product. The 80 mg vial is a marketplace convention, not a regulatory specification. Compounder-to-compounder variability in mass-ratio accuracy, purity, endotoxin load, and component identity is the rule rather than the exception, and certificates of analysis frequently omit mass-spectrometric verification, endotoxin LAL testing, and amino-acid analysis. ## BPC-157 — research doses and routes The Krivic 2006 Achilles tendon-to-bone healing study in male Wistar rats administered BPC-157 at 10 microgram/kg or 10 nanogram/kg by intraperitoneal injection, daily, for 14 days [12]. The Sikiric 1997 nitric oxide and blood pressure work used the same 10 microgram/kg or 10 nanogram/kg intraperitoneal range alongside L-NAME at 5 mg/kg and L-arginine at 100 mg/kg [15]. Oral administration in drinking water at 0.16 microgram/mL has also been used in rodent ligament-healing studies. The Hsieh 2017 HUVEC angiogenesis study worked at nanomolar to micromolar BPC-157 concentrations in cell culture and applied matching concentrations to the chick chorioallantoic membrane in vivo [6]. The GLP-compliant preclinical safety evaluation in rats, dogs, rabbits, and guinea pigs covered single- and repeated-dose intramuscular and intravenous administration; the abstract reports no minimum toxic dose and no lethal dose at the tested ranges [24]. The Lee 2021 retrospective human case series used intra-articular knee injection of BPC-157 alone or with thymosin beta-4; doses were not standardized across patients and the study had no placebo control [2]. The 2025 narrative review highlights a plasma half-life reported under 30 minutes as a clinician-relevant gating fact [7]. ## GHK-Cu — research doses and routes Cell-culture transcriptomic and lung-fibroblast studies worked at 1-10 nM GHK-Cu in cultured human dermal fibroblasts and COPD lung fibroblasts [5, 13]. The Mao 2025 murine DSS-colitis study administered oral gavage GHK-Cu at 20 mg/kg daily for 14 days [22]. The Pyo 2007 hair-follicle work used subcutaneous GHK-Cu injection in rats and nanomolar concentrations in cultured dermal papilla cells [23]. The Pickart 2015 IRB-approved cosmetic-dermatology trials used topical GHK-Cu cream twice daily for 12 weeks in 71 women and daily for 3 months in the 21-woman histology cohort [10]. These are topical cosmetic doses — not systemic injectable doses, and they do not extrapolate to internal use. GHK and KPV are subject to rapid plasma aminopeptidase degradation in unmodified form. Targeted delivery systems — copper-binding for GHK-Cu, PepT1-targeted nanoparticles for KPV, hyaluronic-acid nanocarriers — extend functional tissue exposure in published delivery studies. ## TB-500 / native Tbeta4 — research doses and routes The molecular-mismatch caveat from /research applies to every dose figure in this section. The Sosne 2022 RGN-259 Phase III neurotrophic-keratopathy trial used 0.1% native Tbeta4 ophthalmic solution, topically, six times daily [9]. The Morris 2010 rat embolic-stroke study used native Tbeta4 at 6 mg/kg intraperitoneal every 3 days, starting 24 hours after stroke [25]. The Malinda 1999 dermal-wound study applied native Tbeta4 at 5 microgram in 50 microliter PBS, topically and intraperitoneally [26], and is the paradigm in which fragment-level TB-500 activity is best characterized. Native Tbeta4 in unmodified form circulates with a half-life of approximately 2 hours in humans by ELISA. The TB-500 fragment is N-acetylated to block aminopeptidase cleavage of the N-terminal lysine and improve in vitro stability; pharmacokinetic data on the acetylated fragment in vivo is sparse. Where a 'TB-500' dose appears in vendor literature, that number rarely corresponds to a published peer-reviewed dose. The Sosne 0.1% topical ophthalmic concentration, the Morris 6 mg/kg IP figure, and the Malinda 5 microgram topical figure are the canonical published reference points — all for native Tbeta4, not the fragment. ## KPV — research doses and routes The Dalmasso 2008 colitis study used KPV at 10 nM in cell culture (intestinal epithelial and T-cell lines) and 100 micromolar in drinking water in mice [3]. The Schaible 2013 mouse traumatic-brain-injury study used a single intraperitoneal 1 mg/kg dose, 30 minutes after controlled cortical impact [19]. The 2025 HaCaT keratinocyte PM10 study used 50 microgram/mL in cell culture [20]. The 2017 ex-vivo human-skin transdermal iontophoretic pilot used a current density of 0.5 mA/cm^2 across microporated stratum corneum [11]. The Xiao 2017 hyaluronic-acid-functionalized polymeric-nanoparticle formulation and the 2024 PepT1-targeted KPV/FK506 co-assembly formulation are the strongest preclinical delivery signals; both target inflamed mucosa via PepT1 [17, 18]. KPV's Km at PepT1 is approximately 160 micromolar [3]. ## Half-life and stability summary BPC-157 — plasma half-life reported under 30 minutes [7]. Originally characterized as the 'stable gastric pentadecapeptide' on the basis of stability in human gastric juice, which supports oral-route work in rodents but does not extend the plasma half-life. Native thymosin beta-4 — circulating half-life approximately 2 hours in humans by ELISA. The TB-500 fragment is N-acetylated to improve in-vitro stability; in-vivo plasma data on the fragment is sparse. GHK-Cu and KPV — short reported in-vivo half-lives in unmodified plasma form due to rapid aminopeptidase cleavage. Targeted delivery systems extend functional tissue exposure, and KPV's PepT1-mediated uptake provides selective accumulation in inflamed epithelium and macrophages. The half-life mismatch is the most clinically relevant pharmacokinetic asymmetry in the four-peptide KLOW blend. A single co-administered dose exposes the four mechanisms on very different timescales — relevant context for any attempt to interpret rodent multi-dose protocols as equivalent to a single human research-dose administration. ## References cited on this page [1] Doctor KLOW editorial — composite citation for the canonical four-peptide KLOW research-vial composition (80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg). No FDA-approved or pharmacopeial KLOW combination product exists. Composition reflects the most-cited research-chemical compounder convention; see component citations below. [2] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33112846/ [3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. DOI: 10.1053/j.gastro.2007.10.026 URL: https://pubmed.ncbi.nlm.nih.gov/18061177/ [5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. DOI: 10.3390/ijms19071987 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ [6] Hsieh MJ, Liu HT, Wang CN, Huang HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. DOI: 10.1007/s00109-016-1488-y URL: https://pubmed.ncbi.nlm.nih.gov/27847966/ [7] Multiple authors. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. DOI: 10.1007/s12178-025-09990-7 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ [9] Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2022;24(1):554. DOI: 10.3390/ijms24010554 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/ [10] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. DOI: 10.1155/2015/648108 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ [11] Vemulapalli V, Banga AK, Friden PM. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences. 2017. DOI: 10.1016/j.xphs.2017.04.022 URL: https://www.sciencedirect.com/science/article/abs/pii/S0022354917301740 [12] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. DOI: 10.1002/jor.20096 URL: https://pubmed.ncbi.nlm.nih.gov/16583442/ [13] Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67. DOI: 10.1186/gm367 URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/ [15] Sikiric P, Seiwerth S, Grabarevic Z, Petek M, et al. The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology. 1997;332(1):23-33. DOI: 10.1016/S0014-2999(97)01033-9 URL: https://pubmed.ncbi.nlm.nih.gov/9298922/ [17] Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640. DOI: 10.1016/j.ymthe.2016.12.020 URL: https://pubmed.ncbi.nlm.nih.gov/28143741/ [18] Multiple authors. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Frontiers in Pharmacology. 2024;15:1442876. DOI: 10.3389/fphar.2024.1442876 URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1442876/full [19] Schaible E-V, Steinstraesser A, Jahn-Eimermacher A, Luh C, Sebastiani A, Kornes F, Pieter D, Schaefer MK, Engelhard K, Thal SC. Single Administration of Tripeptide alpha-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice. PLOS ONE. 2013;8(8):e71056. DOI: 10.1371/journal.pone.0071056 URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071056 [20] Multiple authors. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway. Life Sciences. 2025. DOI: 10.1016/j.lfs.2025.123528 URL: https://www.sciencedirect.com/science/article/abs/pii/S004081662500117X [22] Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025;16:1551843. DOI: 10.3389/fphar.2025.1551843 URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1551843/full [23] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. DOI: 10.1007/BF02977780 URL: https://pubmed.ncbi.nlm.nih.gov/17703738/ [24] Xu C, Sun L, Ren F, Huang P, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020. DOI: 10.1016/j.yrtph.2020.104665 URL: https://www.sciencedirect.com/science/article/abs/pii/S027323002030091X [25] Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta-4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. DOI: 10.1016/j.neuroscience.2010.07.029 URL: https://pubmed.ncbi.nlm.nih.gov/20627173/ [26] Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. DOI: 10.1046/j.1523-1747.1999.00608.x URL: https://www.jidonline.org/article/S0022-202X(15)40595-0/fulltext --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.